Primary hyperaldosteronism, an undiagnosed or unsuspected disease?

Versions

PDF (Español (España))
Texto (Español (España))

Keywords

aldosterona
algoritmo diagnóstico
hiperaldosteronismo primario
hipertensión arterial secundaria
renina Aldosterone
Diagnostic algorithm
Primary Hyperaldosteronism
Secondary Hypertension
Renin

How to Cite

Corredor-Rengifo, D., Riveros-Bermúdez , S. D. ., Talat , A., & Román-González , A. (2023). Primary hyperaldosteronism, an undiagnosed or unsuspected disease?. Interdisciplinary Journal of Epidemiology and Public Health, 5(2), e–9884. https://doi.org/10.18041/2665-427X/ijeph.2.9884 (Original work published December 30, 2022)

Abstract

Primary hyperaldosteronism is a condition directly related to arterial hypertension, being the first etiology of secondary origin; given the low suspiciousness the diagnosis is not frequently made, however it has a few steps in the diagnostic protocol that includes measurement of renin aldosterone activity, confirmatory tests such as the saline test and imaging studies such as tomography of the adrenal glands; management can be medical or surgical, impacting on the control of blood pressure and a great number of related pathologies such as atrial fibrillation, obesity and obstructive hypopnea sleep apnea, reducing the high morbidity and mortality of these associated conditions, so it is very important to recognize screening measures and diagnosis of primary hyperaldosteronism.

https://doi.org/10.18041/2665-427X/ijeph.2.9884
PDF (Español (España))
Texto (Español (España))

References

Stowasser M, Gordon RD. Primary aldosteronism: changing definitions and new oncepts of physiology and pathophysiology both inside and outside the kidney. Physiol Rev 2016; 96: 1327–84. doi: 10.1152/physrev.00026.2015.

Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of resistant and refractory hypertension. Circ Res 2019; 124: 1061–70. doi: 10.1161/CIRCRESAHA.118.312156.

González AR, Londoño M del PU de A, Diaz J, Barrera CAB, Gutiérrez J. Incidentaloma adrenal: Acta Médica Colomb. 2015; 40(4):318–25.

Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007; 113: 267–78. doi: 10.1042/CS20070123.

Funder JW, Carey RM. Primary Aldosteronism: Where Are We Now? Where to from Here? Hypertension. 2022; 79(4):726–35. doi: 10.1161/HYPERTENSIONAHA.121.18761.

Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020;173(1):10-20. doi: 10.7326/M20-0065.

Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101: 1889–916. doi: 10.1210/jc.2015-4061.

Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens 2020; 38: 1919–28. doi: 10.1097/HJH.0000000000002510.

Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A; Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J. 2011;58(9):711-21. doi: 10.1507/endocrj.ej11-0133.

Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93(9):3266-81. doi: 10.1210/jc.2008-0104.

Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-300. doi: 10.1016/j.jacc.2006.07.059.

Mulatero P, Sechi LA, Williams TA, Lenders JWM, Reincke M, Satoh F, et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38(10):1929-1936. doi: 10.1097/HJH.0000000000002520.

Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 2021; 9(12):876-892. doi: 10.1016/S2213-8587(21)00210-2.

Rossi GP, Funder JW. Adrenal Venous Sampling Versus Computed Tomographic Scan to Determine Treatment in Primary Aldosteronism (The SPARTACUS Trial): A Critique. Hypertension. 2017;69(3):396-397. doi: 10.1161/HYPERTENSIONAHA.116.08820.

Williams TA, Burrello J, Sechi LA, Fardella CE, Matrozova J, Adolf C, et al. Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension. 2018;72(3):641-649. doi: 10.1161/HYPERTENSIONAHA.118.11382.

Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689-699. doi: 10.1016/S2213-8587(17)30135-3.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2022 Interdisciplinary Journal of Epidemiology and Public Health

Downloads

Download data is not yet available.